Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations

Human Molecular Genetics

Volumn 19, Issue 15, 2010, Pages 2936-2946

  Barekati, Zeinab ^a   Radpour, Ramin ^a   Kohler, Corina ^a   Zhang, Bei ^a   Toniolo, Paolo ^b,c   Lenner, Per ^d   Lv, Qing ^e   Zheng, Hong ^e,f   Zhong, Xiao Yan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e SICHUAN UNIVERSITY   (China)

^f SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; MITOCHONDRIAL DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN P14; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MDM2 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER GENETICS; CLINICAL ARTICLE; CORRELATION ANALYSIS; DNA METHYLATION; EPIGENETICS; GENE MUTATION; GENE SILENCING; GERM LINE; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CONFORMATION; CPG ISLAND; FEMALE; GENETICS; HIGH THROUGHPUT SCREENING; MASS SPECTROMETRY; MIDDLE AGED; MITOCHONDRION; MUTATION; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR GENE;

BREAST NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, MITOCHONDRIAL; FEMALE; GENES, NEOPLASM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MIDDLE AGED; MITOCHONDRIA; MUTATION; NUCLEIC ACID CONFORMATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955549390     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq199     Document Type: Article

References (56)

1. Fukasawa, K., Wiener, F., Vande Woude, G.F. and Mai, S. (1997) Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene, 15, 1295-1302.
2. Mummenbrauer, T., Janus, F., Muller, B., Wiesmuller, L., Deppert, W. and Grosse, F. (1996) p53 Protein exhibits 3'- to -5' exonuclease activity. Cell, 85, 1089-1099.
3. Schwartz, D., Almog, N., Peled, A., Goldfinger, N. and Rotter, V. (1997) Role of wild type p53 in the G2 phase: regulation of the gammairradiation- induced delay and DNA repair. Oncogene, 15, 2597-2607.
4. Sugrue, M.M., Shin, D.Y., Lee, S.W. and Aaronson, S.A. (1997) Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl Acad. Sci. USA, 94, 9648-9653.
5. Almog, N. and Rotter, V. (1997) Involvement of p53 in cell differentiation and development. Biochim. Biophys. Acta, 1333, F1-F27.
6. Heyne, K., Mannebach, S., Wuertz, E., Knaup, K.X., Mahyar-Roemer, M. and Roemer, K. (2004) Identification of a putative p53 binding sequence within the human mitochondrial genome. FEBS Lett., 578, 198-202.
7. Chen, D., Yu, Z., Zhu, Z. and Lopez, C.D. (2006) The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells. Cancer Res., 66, 3485-3494.
8. Lebedeva, M.A., Eaton, J.S. and Shadel, G.S. (2009) Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim. Biophys. Acta, 1787, 328-334.
9. Achanta, G., Sasaki, R., Feng, L., Carew, J.S., Lu, W., Pelicano, H., Keating, M.J. and Huang, P. (2005) Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J., 24, 3482-3492.
10. Polyak, K., Li, Y., Zhu, H., Lengauer, C., Willson, J.K., Markowitz, S.D., Trush, M.A., Kinzler, K.W. and Vogelstein, B. (1998) Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat. Genet., 20, 291-293.
11. Liu, V.W., Shi, H.H., Cheung, A.N., Chiu, P.M., Leung, T.W., Nagley, P., Wong, L.C. and Ngan, H.Y. (2001) High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res., 61, 5998-6001.
12. Rogounovitch, T.I., Saenko, V.A., Shimizu-Yoshida, Y., Abrosimov, A.Y., Lushnikov, E.F., Roumiantsev, P.O., Ohtsuru, A., Namba, H., Tsyb, A.F. and Yamashita, S. (2002) Large deletions in mitochondrial DNA in radiation-associated human thyroid tumors. Cancer Res., 62, 7031-7041.
13. Gochhait, S., Bhatt, A., Sharma, S., Singh, Y.P., Gupta, P. and Bamezai, R.N. (2008) Concomitant presence of mutations in mitochondrial genome and p53 in cancer development-a study in north Indian sporadic breast and esophageal cancer patients. Int. J. Cancer, 123, 2580-2586.
14. Chang, S.C., Lin, P.C., Yang, S.H., Wang, H.S., Liang, W.Y. and Lin, J.K. (2009) Mitochondrial D-loop mutation is a common event in colorectal cancers with p53 mutations. Int. J. Colorectal Dis., 24, 623-628.
15. Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A. et al. (2004) Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol., 24, 5835-5843.
16. Kamijo, T., Weber, J.D., Zambetti, G., Zindy, F., Roussel, M.F. and Sherr, C.J. (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl Acad. Sci. USA, 95, 8292-8297.
17. Onel, K. and Cordon-Cardo, C. (2004) MDM2 and prognosis. Mol. Cancer Res., 2, 1-8.
18. Vousden, K.H. and Lu, X. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2, 594-604.
19. Pharoah, P.D., Day, N.E. and Caldas, C. (1999) Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br. J. Cancer, 80, 1968-1973.
20. Xie, C.H., Naito, A., Mizumachi, T., Evans, T.T., Douglas, M.G., Cooney, C.A., Fan, C.Y. and Higuchi, M. (2007) Mitochondrial regulation of cancer associated nuclear DNA methylation. Biochem. Biophys. Res. Commun., 364, 656-661.
21. Silva, J., Dominguez, G., Silva, J.M., Garcia, J.M., Gallego, I., Corbacho, C., Provencio, M., Espana, P. and Bonilla, F. (2001) Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene, 20, 4586-4590.
22. Quesnel, B., Preudhomme, C., Fournier, J., Fenaux, P. and Peyrat, J.P. (1994) MDM2 gene amplification in human breast cancer. Eur. J. Cancer, 30A, 982-984.
23. Deb, S.P. (2003) Cell cycle regulatory functions of the human oncoprotein MDM2. Mol. Cancer Res., 1, 1009-1016.
24. Ueda, K., Nishijima, M., Inui, H., Watatani, M., Yayoi, E., Okamura, J., Yasutomi, M., Nakamura, Y. and Miyoshi, Y. (1998) Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Jpn. J. Cancer Res., 89, 17-21.
25. Trimboli, A.J., Cantemir-Stone, C.Z., Li, F., Wallace, J.A., Merchant, A., Creasap, N., Thompson, J.C., Caserta, E., Wang, H., Chong, J.L. et al. (2009) Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature, 461, 1084-1091.
26. Moll, U.M. and Petrenko, O. (2003) The MDM2-p53 interaction. Mol. Cancer Res., 1, 1001-1008.
27. Lin, A.W. and Lowe, S.W. (2001) Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl Acad. Sci. USA, 98, 5025-5030.
28. Mayo, L.D., Dixon, J.E., Durden, D.L., Tonks, N.K. and Donner, D.B. (2002) PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem., 277, 5484-5489.
29. Zhou, B.P., Liao, Y., Xia, W., Zou, Y., Spohn, B. and Hung, M.C. (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol., 3, 973-982.
30. Freeman, D.J., Li, A.G., Wei, G., Li, H.H., Kertesz, N., Lesche, R., Whale, A.D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R.D. et al. (2003) PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell, 3, 117-130.
31. Kern, S.E., Kinzler, K.W., Baker, S.J., Nigro, J.M., Rotter, V., Levine, A.J., Friedman, P., Prives, C. and Vogelstein, B. (1991) Mutant p53 proteins bind DNA abnormally in vitro. Oncogene, 6, 131-136.
32. Radpour, R., Kohler, C., Haghighi, M.M., Fan, A.X., Holzgreve, W. and Zhong, X.Y. (2009) Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene, 28, 2969-2978.
33. Herman, J.G. and Baylin, S.B. (2003) Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 349, 2042-2054.
34. Sharma, G., Mirza, S., Prasad, C.P., Srivastava, A., Gupta, S.D. and Ralhan, R. (2007) Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci., 80, 1873-1881.
35. Muggerud, A.A., Ronneberg, J.A., Warnberg, F., Botling, J., Busato, F., Jovanovic, J., Solvang, H., Bukholm, I., Borresen-Dale, A.L., Kristensen, V.N. et al. (2010) Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res., 12, R3.
36. Khan, S., Kumagai, T., Vora, J., Bose, N., Sehgal, I., Koeffler, P.H. and Bose, S. (2004) PTEN promoter is methylated in a proportion of invasive breast cancers. Int. J. Cancer, 112, 407-410.
37. Garcia, J.M., Silva, J., Pena, C., Garcia, V., Rodriguez, R., Cruz, M.A., Cantos, B., Provencio, M., Espana, P. and Bonilla, F. (2004) Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer, 41, 117-124.
38. Silva, J., Silva, J.M., Dominguez, G., Garcia, J.M., Cantos, B., Rodriguez, R., Larrondo, F.J., Provencio, M., Espana, P. and Bonilla, F. (2003) Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J. Pathol., 199, 289-297.
39. Trotman, L.C. and Pandolfi, P.P. (2003) PTEN and p53: who will get the upper hand? Cancer Cell, 3, 97-99.
40. Fan, A.X., Radpour, R., Haghighi, M.M., Kohler, C., Xia, P., Hahn, S., Holzgreve, W. and Zhong, X.Y. (2009) Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer. J. Cancer Res. Clin. Oncol., 135, 983-989.
41. Xia, P., An, H.X., Dang, C.X., Radpour, R., Kohler, C., Fokas, E., Engenhart-Cabillic, R., Holzgreve, W. and Zhong, X.Y. (2009) Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer, 9, 454.
42. Kohler, C., Radpour, R., Barekati, Z., Asadollahi, R., Bitzer, J., Wight, E., Burki, N., Diesch, C., Holzgreve, W. and Zhong, X.Y. (2009) Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol. Cancer, 8, 105.
43. Tseng, L.M., Yin, P.H., Chi, C.W., Hsu, C.Y., Wu, C.W., Lee, L.M., Wei, Y.H. and Lee, H.C. (2006) Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer, 45, 629-638.
44. Hibi, K., Robinson, C.R., Booker, S., Wu, L., Hamilton, S.R., Sidransky, D. and Jen, J. (1998) Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res., 58, 1405-1407.
45. Esteller, M., Sanchez-Cespedes, M., Rosell, R., Sidransky, D., Baylin, S.B. and Herman, J.G. (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res., 59, 67-70.
46. Sanchez-Cespedes, M., Esteller, M., Wu, L., Nawroz-Danish, H., Yoo, G.H., Koch, W.M., Jen, J., Herman, J.G. and Sidransky, D. (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res., 60, 892-895.
47. Muller, H.M., Widschwendter, A., Fiegl, H., Ivarsson, L., Goebel, G., Perkmann, E., Marth, C. and Widschwendter, M. (2003) DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res., 63, 7641-7645.
48. Dulaimi, E., Hillinck, J., Ibanez de Caceres, I., Al-Saleem, T. and Cairns, P. (2004) Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin. Cancer Res., 10, 6189-6193.
49. Fujiwara, K., Fujimoto, N., Tabata, M., Nishii, K., Matsuo, K., Hotta, K., Kozuki, T., Aoe, M., Kiura, K., Ueoka, H. et al. (2005) Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res., 11, 1219-1225.
50. Leon, S.A., Shapiro, B., Sklaroff, D.M. and Yaros, M.J. (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res., 37, 646-650.
51. Zhong, X.Y., Ladewig, A., Schmid, S., Wight, E., Hahn, S. and Holzgreve, W. (2007) Elevated level of cell-free plasma DNA is associated with breast cancer. Arch. Gynecol. Obstet., 276, 327-331.
52. Radpour, R., Sikora, M., Grussenmeyer, T., Kohler, C., Barekati, Z., Holzgreve, W., Lefkovits, I. and Zhong, X.Y. (2009) Simultaneous Isolation of DNA, RNA, and proteins for genetic, epigenetic, transcriptomic, and proteomic analysis. J. Proteome Res., 8, 5264-5274.
53. Ehrich, M., Nelson, M.R., Stanssens, P., Zabeau, M., Liloglou, T., Xinarianos, G., Cantor, C.R., Field, J.K. and van den Boom, D. (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc. Natl Acad. Sci. USA, 102, 15785-15790.
54. Li, L.C. and Dahiya, R. (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics, 18, 1427-1431.
55. Xia, P., Radpour, R., Zachariah, R., Fan, A.X., Kohler, C., Hahn, S., Holzgreve, W. and Zhong, X.Y. (2009) Simultaneous quantitative assessment of circulating cell-free mitochondrial and nuclear DNA by multiplex real-time PCR. Genet Mol. Biol., 32, 20-24.
56. Radpour, R., Barekati, Z., Haghighi, M.M., Kohler, C., Asadollahi, R., Torbati, P.M., Holzgreve, W. and Zhong, X.Y. (2010) Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. Mod. Pathol., 23, 763-772.